Lebanese Forces
Lebanese Forces
Ready to play
Ready to play
A recent study has shown that the Human Papillomavirus (HPV) vaccine may reduce men's risk of developing head and neck cancers by up to 70%. The study analyzed data from 1.4 million people in the United States, including over 700,000 who received the vaccine originally intended for women. It was found that 40 vaccinated individuals developed head and neck cancers compared to 130 unvaccinated individuals. The virus has been linked to multiple cancers, particularly throat and tonsil cancers, causing approximately 16,000 cases annually in the U.S., with 85% of these cases occurring in men. Although the results suggest potential protection, they are not definitive and require broader and longer-term studies to confirm the vaccine's effectiveness in directly preventing these cancers. The United States recommends vaccination for young people up to age 26 and advocates expanding vaccination efforts to include both males and females, as HPV affects several types of cancers beyond cervical cancer.
Notice: This Is an AI-Generated Summary
Comments (0)